1490 results about "Toxin" patented technology

The invention provides conotoxin-derived anticoagulant polypeptide Cb-13 and application thereof, and belongs to the technical field of biological medicine. The invention provides an anticoagulant polypeptide Cb-13. The amino acid sequence of the anticoagulant polypeptide Cb-13 comprises SEQ ID No.1. The invention also provides a coding gene of the anticoagulant polypeptide Cb-13, and provides that the anticoagulant polypeptide Cb-13 does not have hemolytic activity and does not have cytotoxicity when the concentration is 400 [mu] M or below. The anticoagulant polypeptide Cb-13 disclosed by the invention has a prolonging effect on plasma recalcification and coagulation time, has an anticoagulant effect, has small influence on bleeding, and also has an obvious promoting effect on plasmin and uPa. Meanwhile, it is also proved that the anticoagulant polypeptide Cb-13 can inhibit thrombus formation, that is, the anticoagulant polypeptide Cb-13 has in-vivo and in-vitro fibrinolytic effect and anticoagulant effect, has small bleeding risk, and can be used as an antithrombotic or thrombolytic drug.

The invention discloses an anti-EV71 virus activity buthus martensii toxin polypeptide as well as a preparation method and application thereof, and belongs to the technical field of antiviral preparations. A scorpion tail electricity-saving stimulation method is adopted to obtain crude scorpion venom, and centrifugation and freeze drying are performed to obtain scorpion venom freeze-dried powder; dissolving the scorpion toxin freeze-dried powder, filtering, removing sediment, carrying out ultrafiltration centrifugation, and separating to obtain the anti-EV71 virus activity scorpion toxin polypeptide. According to the present invention, the scorpion martensii toxin polypeptides S-I (lt; 3kDa) and S-II (3-10 kDa) obtained from the scorpion martensii have good EV71 virus resistance; under the same concentration, the relative molecular mass is lt; compared with the prior art, the scorpion margaritae toxin polypeptide with the molecular weight of 3kDa has better anti-EV71 virus activity, has no toxic effect on cells, has the potential of being used as an anti-EV71 virus drug, and provides a theoretical basis for biomedical research and clinical application of the scorpion margaritae toxin polypeptide.

The invention relates to the technical field of artificial intelligence, and discloses a method and a system for dynamically predicting the risk of harm of feed mycotoxin to livestock and poultry. The method comprises the following steps: constructing a metabolic digital twin model based on a multi-organ coupling dynamics mechanism, connecting a gastrointestinal tract, a liver and a kidney through blood flow parameters to form a closed loop topology network, establishing a toxin migration rate equation, and verifying bioavailability; collecting feed toxin concentration and livestock and poultry physiological data in real time; after distributing the initial toxin load, iteratively generating target organ dynamic concentration distribution by adopting a Runge-Kutta method; an organ exposure index is calculated based on an organ specific hazard threshold, key organs are positioned, and low / high risk levels and toxin accumulation paths are output. The method solves the problems that a traditional static model is low in efficiency and poor in organ difference adaptability when being used for dynamically predicting the risk of harm to livestock and poultry caused by feed mycotoxin.

The invention provides a group of specific antibodies for detecting botulinum toxin A and application thereof, and belongs to the technical field of botulinum toxin detection. The invention provides a group of specific antibodies for detecting botulinum toxin A or antigen binding fragments thereof. The specific antibodies or the antigen binding fragments thereof comprise a rabbit monoclonal antibody 1F11 or an antigen binding fragment thereof and a rabbit monoclonal antibody 2A10 or an antigen binding fragment thereof. The time-resolved immunodetection kit prepared by the invention has good detection sensitivity, specificity, repeatability and sample matrix tolerance, the detection range is 0.02 ng / mL-10 ng / mL, the detection limit is 0.02 ng / mL, cross reaction with other serotype botulinum toxins (B, E and F) does not exist, and the time-resolved immunodetection kit is not influenced by sample matrixes such as ham sausages and thick broad-bean sauce. The detection system established by the invention has a good application prospect in detection of botulinum toxin type A.

The invention relates to an adjusting system applied to continuous kidney replacement treatment of acute kidney injury patients. Comprising the following steps: capturing the blood flow velocity and vascular endothelial permeability of glomerular capillaries in real time by using a micro sensor or a nano-scale optical imaging technology; the method comprises the following steps: pre-judging a risk time point of insufficient tissue perfusion through dynamic modeling of a capillary structure and a functional relationship; combining the microcirculation data with conventional biochemical indexes of the patient to create an early intervention model; when it is monitored that microcirculation perfusion is greatly reduced or kidney oxygen supply is insufficient, continuous renal replacement therapy CRRT parameter fine adjustment is triggered in advance; the method comprises the following steps: collecting plasma toxins of different patients at clinical and molecular levels, and constructing a common toxin map of the acute kidney injury AKI; whether the specific toxin concentration exceeds the standard or not is judged by combining a real-time sensor, and the removal priority is output in real time; a membrane material with an adjustable aperture or a special coating is adopted, so that inflammatory mediators and bacterial endotoxin molecules are adsorbed or intercepted, and the permeability of micromolecular electrolyte is kept.

The invention provides a method for detecting the average coupling rate of an antibody-coupled drug based on small molecule extinction coefficient correction and application of the method. The method comprises the following steps: firstly, measuring the absorbance and extinction coefficient of L-cysteine-linker-toxin molecules at 280nm, and then calculating and correcting to obtain the accurate average coupling rate of the antibody coupling medicine based on the measured absorbance and extinction coefficient and liquid chromatogram conditions. According to the method, in the analysis process, through the extinction coefficient of L-cysteine-connexon-toxin molecules at the wavelength of 280 nm, the area of a liquid chromatogram peak which is collected at the wavelength of 280 nm and is reduced by ADC is corrected, so that the measured average coupling rate result is more accurate and real. Besides, the method is suitable for the antibody-coupled drug obtained in a cysteine coupling mode, and is especially suitable for the antibody-coupled drug which is strong in coupled micromolecule ultraviolet absorption and has obvious influence on a DAR result.

The invention discloses an application of an MDH2 knockout system or inhibitor in reducing toxicity of T-2 toxin, and belongs to the technical field of biological agents. An MDH2 knockout IPEC-J2 cell line is constructed through a CRISPR / Cas9 gene editing system, and it is found that the cell activity of the cell line is remarkably improved under the condition of 20 ng / mLT-2 toxin concentration, the cell death rate is remarkably reduced, and the cell line has obvious resistance to T-2 toxin. The MDH2 inhibitor LW6 can also enhance the resistance of the cells to T-2 toxin when being used for treating the cells. Therefore, the toxicity of the T-2 toxin in the cell can be reduced by knocking out the MDH2 gene in the IPEC-J2 cell and inhibiting the activity of the MDH2, the tolerance of the cell to the T-2 toxin is improved, and a theoretical basis is provided for prevention and control of harm of the T-2 toxin to human and animals.

The invention discloses lysinibacillus sp. For degrading alternaria alternata toxins and application of the lysinibacillus sp., and belongs to the technical field of microorganisms, the lysinibacillus sp. Is preserved in China Center for Type Microbiological Culture Collection, the preservation address is Wuhan University, Hubei Province, and the preservation number is CCTCC No.M20241816. The invention further discloses a preparation method of the lysinibacillus sp. According to the invention, the Lysinibacillus macroides capable of effectively reducing and degrading alternaria alternata toxin is obtained for the first time, and the quality of agricultural products (including aquatic products) is favorably improved.

The invention relates to streptomyces cell and application thereof in efficient degradation of aflatoxin B1, the streptomyces cell is streptomyces cell AFB1-D02, and has been preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.33986, and the preservation date is March 26, 2025. The invention further discloses a preparation method of the streptomyces cell. The streptomycete S. cellostatus AFB1-D02 has the capability of efficiently degrading AFB1, and the degradation efficiency of the streptomycete S. cellostatus AFB1-D02 is obviously higher than that of other streptomycetes in the prior art.

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. The methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

According to the application of the bacteriophage to reduction of cholera transmission, the bacteriophage phi YSZKA is preserved in the China Center for Type Culture Collection on August 1, 2018, the preservation number is CCTCC NO: M 2018513, and the bacteriophage phi YSZKA is classified and named as klebsiella pneumoniae bacteriophage phi YSZKA. The method solves the problems of secondary pollution, wide transmission of vibrio cholerae and the like of the traditional split bacteriophage. The application of the bacteriophage can reduce the toxin production efficiency of vibrio cholerae in oceans, soil and sewers, thereby providing more possibilities for prevention and control of cholera epidemic situation and alleviation of cholera symptoms.

The invention belongs to the technical field of protein, and relates to an active peptide for enhancing intestinal barrier function and a preparation method and application thereof, and the amino acid sequence of the peptide is LIPR. According to the active peptide, the intestinal barrier function is enhanced by promoting expression of sealing protein, closing protein and ZO-1 protein, so that toxin invasion is reduced, and intestinal health is maintained. The invention also provides a preparation method and application of the active peptide for enhancing the intestinal barrier function.

The disclosure provides an extracorporeal devices, systems and methods for removing a pathogen or a toxin from a biological fluid of a subject comprising contacting a biological fluid from the subject with a loosely packed bed of adsorption media, such as a fluidized bed, wherein the adsorption media comprises heparin, to remove the pathogen or the toxin to form a treated biological fluid; and infusing the treated fluid into the subject.

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an iNOS inhibitor in preparation of a medicine for relieving cellular injury caused by toxin combined exposure. KK-1 cells serve as a research model, it is shown for the first time that MC-LR and NaNOS combined contamination can remarkably up-regulate the expression level of iNOS protein, and it is found through tests that Nos2 gene silencing can remarkably relieve tight junction damage and cell apoptosis caused by toxin combined exposure in the KK-1 cells; it is revealed for the first time that iNOS is a core target of toxin combined exposure induced cell tight junction damage and apoptosis, and the blank of toxic mechanism research in toxin combined exposure is filled. The application provides a new direction for a detoxification strategy of environmental toxin combined exposure, provides a theoretical basis for developing an iNOS-targeted inhibitor, and also provides a new target for etiological recognition, early diagnosis and prevention of related diseases caused by environmental toxin combined exposure.

Provided, inter alia, are antibody-conjugated drugs (ADCs) comprising novel camptothecin derivative toxins. Further disclosed are pharmaceutical compositions and methods for treating cancer using the ADCs provided herein.

The invention provides a chemically modified tetanus toxin C fragment as well as preparation and application thereof. The method for chemically modifying the tetanus toxin C fragment comprises the following steps: 1) reacting the tetanus toxin C fragment with a reducing agent to reduce a disulfide bond in the tetanus toxin C fragment; and 2) carrying out a reaction on the reduced tetanus toxin C fragment and an alkylation reagent, and carrying out modification. The recombinant tetanus toxin C fragment prepared by the method disclosed by the invention not only meets the quality standard required by pharmacopeia, but also has the advantages of stable conformation, high yield, easiness in amplification and low cost, and has a wide application prospect in the preparation of human vaccines, veterinary vaccines and antibody drugs and the development process of in-vitro diagnostic reagents.

The invention provides a subunit vaccine for resisting poultry clostridium perfringens, which is characterized in that CPA and NetB proteins are truncated, and three gene sequences of auxiliary protease Fba are connected in series and fused through Linker to obtain recombinant protein. Immunogenicity detection on the N-C-F recombinant protein finds that the N-C-F recombinant protein can induce SPF chicken to generate antibodies. Immune protection test results show that the subunit vaccine prepared from the N-C-F protein and the adjuvant can achieve 100% immune protection effect when being used for immunizing 100 [mu] g / chicken and 200 [mu] g / chicken, and the subunit vaccine can be used as a subunit vaccine for resisting various toxin types.

The invention relates to a microbial agent for preventing and treating root rot of radix tinosporae and application of the microbial agent. The microbial agent is prepared from the following components: bacillus velezensis with the preservation number of CCTCC (China Center for Type Culture Collection) No: M2022923, bacillus subtilis with the preservation number of CCTCC No: M20221207, a marigold extract, amino acid, humic acid and medium trace elements. When the microbial agent is applied to the planting process of radix tinosporae, the physicochemical property of radix tinosporae planting soil can be remarkably improved, the enzyme activity and the microbial diversity can be improved, the content of phenolic acid and fusarium toxin in the soil can be reduced, the disease index of radix tinosporae root rot caused by fusarium solani and pythium aphanidermatum can be further reduced, and finally prevention and control of radix tinosporae root rot can be achieved.

The present application describes in part isolated and modified Enterococci toxin (Epx) polypeptides, immunogenic compositions comprising Exp polypeptides, nanopores formed by Epx polypeptides, apparatus comprising Epx nanopores, and methods of use thereof.

The invention discloses a strain of Bifidobacterium breve capable of removing toxins in a body and a metagen of the Bifidobacterium breve, and belongs to the technical field of microbial application, the Bifidobacterium breve WZA-BB07 is separated from human excrement, and the biological preservation number of the Bifidobacterium breve WZA-BB07 is CCTCC (China Center for Type Culture Collection) NO: M20241530. The bacterial strain WZA-BB07 has a good effect of degrading endotoxin and enterotoxin, the bacterial strain and lactobacillus reuteri are subjected to mixed fermentation to prepare the postbiotics, bifidobacterium breve mainly improves intestinal flora balance and inhibits growth of harmful bacteria, the lactobacillus reuteri helps repair intestinal barriers through metabolites of the lactobacillus reuteri in the fermentation process, and the lactobacillus reuteri and lactobacillus reuteri are mixed to prepare the postbiotics. Metabolism and removal of toxins are enhanced; dendrobium officinale, honeysuckle and radix puerariae extracts are added into a fermentation culture medium, so that rich nutrition is provided for fermentation, the effects of resisting oxidation, resisting inflammation and promoting intestinal repair of medicinal and edible components are also exerted, and the detoxification capacity and the overall health effect of the postbiotic product are further improved.

The invention discloses a monoclonal antibody against abrus precatorius toxin and application thereof, belongs to the field of biological medicine, and provides a monoclonal antibody against abrus precatorius toxin, which has at least 95%, at least 96%, at least 97%, at least 98% and at least 99% sequence identity with amino acid sequences shown as SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, of heavy chain variable region complementarity determining regions CDR1, CDR2 and CDR3. The light chain variable region complementarity determining regions CDR1, CDR2 and CDR3 have at least 95%, at least 96%, at least 97%, at least 98% and at least 99% of amino acid sequences shown as SEQ ID NO: 9, 10 and 11. The invention further provides application of the antibody to preparation of an antibody for detecting and treating abrus precatorius toxin poisoning and having a long-time treatment effect and related products.

The invention relates to a reagent for detecting amatoxin in blood and a detection method thereof. The detection reagent for the amatoxin in the blood comprises an extraction tube, a dilution tube and a standard gradient solution, the extraction tube contains 1.5 mL of acetonitrile, the dilution tube contains 400 [mu] L of a 1% acetic acid aqueous solution, and the gradient concentrations of the standard gradient solution are 1 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, 50 ng / mL and 100 ng / mL. The method provided by the invention effectively solves the problem of poor signal stability of amatoxin in a blood sample, and meanwhile, complex steps such as solid-phase extraction do not need to be adopted in the detection process, so that the detection time is saved, and a technical support is provided for emergency monitoring of public health emergencies.

The present invention discloses a Bifidobacterium breve strain capable of clearing toxins in the body and its postbiotics, belonging to the technical field of microbial applications. The present invention isolates a Bifidobacterium breve strain ( Bifidobacterium breve ) WZA-BB07 from human feces, and its biological deposit number is: CCTCC NO: M20241530. The strain WZA-BB07 has good effects in degrading endotoxin and enterotoxin. The strain and Lactobacillus mucosae are mixed and fermented to prepare postbiotics. Bifidobacterium breve mainly improves the balance of intestinal flora and inhibits the growth of harmful bacteria. Lactobacillus mucosae helps repair the intestinal barrier through its metabolites during fermentation, enhancing the metabolism and clearance of toxins; extracts of Dendrobium officinale, Lonicera japonica, and Pueraria lobata are added to the fermentation medium, which not only provides rich nutrition for fermentation but also exerts the antioxidant, anti-inflammatory, and intestinal repair-promoting effects of ingredients with both medicinal and edible properties, further enhancing the detoxification ability and overall health effects of the postbiotic product.

The invention belongs to the technical field of bioengineering, and particularly relates to a zearalenone toxin degrading enzyme variant and application thereof. The amino acid sequence of the zearalenone toxin degrading enzyme is as shown in SEQ ID NO.2, or the zearalenone toxin degrading enzyme with the amino acid sequence as shown in SEQ ID NO.2 is obtained through amino acid mutation. The zearalenone toxin degrading enzyme mutant is obtained through mutation screening, and compared with a wild type, the zearalenone toxin degrading enzyme mutant has the advantages that the zearalenone degrading capability is obviously improved; besides, the zearalenone toxin degrading enzyme is expressed by using alfalfa, the zearalenone toxin degrading enzyme with biological activity is easy to obtain, and the zearalenone toxin degrading enzyme has certain application potential in prevention and treatment of animal poisoning caused by zearalenone toxin pollution in agriculture and animal husbandry production.

The invention provides a metal organic framework composite adsorbent, a preparation method thereof and a hemoperfusion device, and belongs to the technical field of blood purification adsorption materials. The metal organic framework composite adsorbent provided by the invention is a metal organic framework material-polysulfone material composite sphere, the metal organic framework material has excellent adsorbability to various toxins, and the polysulfone material has good biocompatibility, mechanical strength, processing adaptability and sterilization capability; therefore, the metal organic framework composite adsorbent has good blood compatibility and toxin adsorbability, is less in adsorbent particle falling, and is suitable for the field of whole blood perfusion. The result of the embodiment shows that the metal organic framework composite adsorbent provided by the invention has excellent adsorption performance on p-cresol sulfate, indoleacetic acid, bilirubin, bile acid and endotoxin, and shows excellent blood compatibility.

The invention discloses a system and a method for analyzing neurotoxicity of cyanobacteria toxin to aquatic organisms, the system comprises a bottom plate, and also comprises an electric guide rail mechanism arranged on the bottom plate, and a bearing container mechanism arranged on a slide block of the electric guide rail mechanism; the first liquid feeding mechanism and the second liquid feeding mechanism are both arranged on the bottom plate; and the full-automatic fluorescent microscope is arranged on the bottom plate and located on the downstream of the second liquid feeding mechanism, an image acquisition module is arranged on an eyepiece of the full-automatic fluorescent microscope, and the image acquisition module is in communication connection with an analysis module. CYN solutions with different concentrations are injected into the placement groove through the first liquid feeding mechanism, a fixed solution is injected into the placement groove through the second liquid feeding mechanism, then the result of the influence of the CYN solutions with different concentrations on aquatic organisms is obtained through analysis of the full-automatic phosphor microscope, the image acquisition module and the analysis module, use is convenient, and the detection accuracy is high. And the labor intensity of workers is reduced.

The invention provides an application of an anti-tetanus toxin antibody in prevention or treatment of tetanus. The anti-tetanus toxin antibody is applied according to a specific administration scheme, and the technical effects that the anti-tetanus toxin antibody takes effect more quickly and the protection time is longer than that of an existing passive immune preparation can be achieved, so that tetanus can be effectively prevented or treated.

This invention is related to the field of biosensors. In particular, devices and methods are described which enable the quantification of biomolecules by virtue of particle speed driven by induced-charge electrophoresis. For example, a range of biomolecules can be simultaneously detected in a highly sensitive manner from a library (e.g., combination) of active particles having different shapes or fluorescent signatures. Such biomolecules are related to conditions including, but not limited to, cancer biomarkers, viral infection biomarkers, toxins, pesticides, and small molecule drugs.

The invention discloses a colorimetric aptamer sensor and application thereof, and belongs to the technical field of biological detection. The colorimetric aptamer sensor comprises Cas12a protein, HP, crRNA, dsDNA (double-stranded deoxyribonucleic acid) and a colorimetric probe. The colorimetric biosensor is applied to detection of the ochratoxin A, the content of the ochratoxin A is detected through the colorimetric biosensor, and detection and analysis of a target object can be achieved; cas12a aptamer inhibitors are developed as molecular switches for biosensors, which mediate target recognition through engineering modification of HP hairpin sequences. A new thought for improving the mycotoxin detection sensitivity is explored, and good detection potential is expected to be shown in the field of food safety.

Described herein are anti-MUC1* antibodies or antibody fragments and antibody drug complex (ADC) comprising an anti-MUC1* antibody conjugated via a linker to a toxin. The present disclosure also provides compositions comprising the antibodies and antibody drug complexes and methods for treating diseases and disorders such as cancer.